Navigation Links
Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
Date:9/30/2008

RICHMOND, Calif., Oct. 1 /PRNewswire/ -- Lumiphore, Inc., a biotechnology leader in the development of new proprietary fluorescent metal-lanthanide technology for use in high-value applications, announced that it has signed an exclusive agreement with Biophor Diagnostics, Inc., Redwood City, California to apply Lumiphore products in diagnostic tests for drugs of abuse.

Under the agreement, Biophor Diagnostics holds the exclusive worldwide rights to Lumi4(TM) technology in current and future diagnostic tests of this type. Lumi4(TM) fluorescent metal-reporter compounds bring increased sensitivity, stability, and robustness to assays in the drugs of abuse testing market through their excellent fade-resistant photophysical properties.

This is the third strategic partnership reached by Lumiphore in the past three years. Previous partnerships include Cis Bio International (http://www.htrf.com/company/partners/) for the drug discovery research market and Echelon Biosciences Inc. (http://www.echelon-inc.com) for novel cancer assays involving phospholipid signaling and lipid-protein interactions.

The company today also announced the appointment of Dr. David J. Ecker to its board of directors. Dr. Ecker is Chief Scientific Officer and a founder of Ibis Biosciences and a co-founder and Vice President of Isis Pharmaceuticals. He brings to the board deep experience in successful biotech commercialization as well as specific technical expertise in detection and assay platforms.

Dr. Ecker has over 24 years of experience in the pharmaceutical/biotechnology industry in cancer and infectious disease research and development. He was a primary inventor of the Ibis T5000 biosensor technology, and has authored more than 80 scientific publications and over 50 U.S. patents. His extensive publications span biosensor technology, infectious disease research, biodefense and gene construction/expression. His previous experience includes assistant director, Department of Molecular Genetics at SmithKline and French (now GlaxoSmithKline).

About Lumiphore | Based in Richmond, California, Lumiphore is a biotechnology leader in the development of proprietary fluorescent-metal lanthanide technology for use in high-value applications which are commercialized through market-specific alliances with corporate partners. Lumiphore has exclusive licenses to the basic science developed at the University of California, Berkeley in the laboratory of Professor Kenneth N. Raymond, a world expert on lanthanide chemistry. Metal lanthanide reporters provide increased sensitivity for fluorescent reagents in biology through time-resolved detection which vastly improves assay signals over background noise. For more information about Lumiphore, log onto http://www.lumiphore.com.

Lumi4(TM) is a trademark of Lumiphore, Inc.

CONTACT: Stephen Blose, +1-415-381-4457, for Lumiphore, Inc.


'/>"/>
SOURCE Lumiphore, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
2. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
3. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
4. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
5. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
7. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
8. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
9. AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
10. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
11. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief ... ), Inc. has been selected for membership in ARCS Alumni Hall of ...
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking events ... announced today. The bold new look is part of a transformation to increase ... a significant growth period. , It will also expand its service offering from its ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced Design ... will feature emerging and evolving technology through its ... Summits will run alongside the expo portion of the ... panels and demonstrations focused on trending topics within 3D ... design and manufacturing event will take place June 13-15, 2017 ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):